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Summary Congenital adrenal hyperplasia is a group of
autosomal recessive disorders resulting from the defi-
ciency of one of the five enzymes required for the
synthesis of cortisol in the adrenal cortex. The most
frequent is steroid 21-hydroxylase deficiency, account-
ing for more than 90% of cases. Much has been
learned about the genetics of the various clinical forms
of 21-hydroxylase deficiency, and correlations between
the genotype and the phenotype have been studied
extensively. Gene-specific diagnosis is now feasible
and neonatal screening and prenatal treatment have
been widely implemented. This discussion will be
limited to the most common form of congenital
adrenal hyperplasia, with focus on the diagnostic
advances in this disease.
Abbreviations
11"-OHD 11"-hydroxylase deficiency
17-OHP 17-hydroxyprogesterone
21-OHD 21-hydroxylase deficiency
CAH congenital adrenal hyperplasia
DBS dried blood spots
DSD disorder of sex development
LDR ligase detection reaction
MLPA multiplex ligation-dependent
probe amplification
Introduction
Congenital adrenal hyperplasia (CAH) is one of the
most frequent inborn endocrine disorders; it comprises
autosomal recessive disorders of cortisol biosynthesis
in the adrenal gland caused by various enzyme
deficiencies. The consequent compensatory rise of
ACTH production causes hyperplastic growth of the
adrenal glands. Blocks of the initial steps of the
steroidogenic pathway impair the production of all
the three types of steroids, i.e. mineralocorticoids,
glucocorticoids and sex hormones, causing abnormal-
ities in the salt–water homeostasis and in sexual
differentiation.
21-Hydroxylase deficiency (21-OHD) accounts for
most cases of CAH (80–90%, depending on the ethnic
group) (Miller 1994; Miller and Levine 1987). Clinical
consequences of 21-OHD arise from overproduction
of androgens. Affected females with the classic 21-
OHD are born with ambiguous genitalia. Postnatally,
untreated patients of both sexes manifest rapid somat-
ic growth with accelerated skeletal maturation, early
closure of the epiphyses, and short adult stature. Other
symptoms include excessive pubic and body hair and
decreased fertility. Seventy-five per cent of patients
with classic 21-OHD also have reduced synthesis of
aldosterone with salt loss. Patients with nonclassic
disease are born without symptoms of prenatal andro-
gen exposure. Subsequently they may remain asymp-
tomatic or may develop signs of androgen excess.
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Deficiency of 21-hydroxylase is inherited as an auto-
somal recessive trait closely linked to the HLA major
histocompatibility complex on the short arm of chro-
mosome 6. While classic 21-OHD is found in about 1
in 16 000 births, nonclassic deficiency is far more
frequent, occurring in up to 3% of persons among
certain ethnic groups (Speiser et al 1985). The clinical
presentation of patients with CAH is heterogeneous
and depends on the type of gene mutation as well as on
the sex of the patient (Hughes 1998). Some newborns
with CAH may thus present without clinical signs or
symptoms postnatally and in these the diagnosis of
CAH obviously cannot be made on clinical basis. The
unrecognized and thus untreated disease may entail
life-threatening salt-wasting crisis in the newborn
period and lead to morbidity later in life, including
precocious puberty and short stature. Thus it is evident
that implementation of a programme that fulfills the
feasibility criteria of neonatal screening is beneficial
in preventing delayed diagnosis of CAH and its
associated morbidity and mortality sequelae (Honour
and Torresani 2001; Pang et al 1977).
The most feasible biochemical marker for the diag-
nosis of CAH is 17-hydroxyprogesterone (17-OHP), the
steroid metabolite lying just upstream the block (Fig. 1).
Screening for CAH by measuring 17-OHP levels in
dried blood spots (DBS) of newborns was incorporat-
ed in the Swiss neonatal screening programme for
metabolic and endocrine diseases at the end of 1992. It
can detect most forms of 21-OHD and some cases of
11b-hydroxylase deficiency (11b-OHD). All other, far
less frequent, enzyme deficiencies of the adrenal gland
leading to CAH cannot be found with this screening
parameter.
Comparatively, all other adrenal enzyme deficien-
cies leading to CAH are relatively rare. Briefly, in
lipoid adrenal hyperplasia no conversion of cholesterol
to any steroid takes place. This rare cause of CAH is
characterized by salt loss and disorder of sex develop-
ment (DSD) in XY individuals. In XX subjects internal
and external genitalia are female, and the syndrome
cannot clinically be separated from congenital adrenal
hypoplasia . The molecular bases of such a defect have
recently been clarified as mutations in the steroidogen-
ic acute response protein (StAR). 17a-Hydroxylase
deficiency, leads to 46, XY DSD due to the lack of
precursors for testosterone. In XX individuals, there is
primary amenorrhoea and absent development of
oestrogenic secondary sexual characteristics. Both
sexes display hypertension and hypokalaemic alkalosis
due to accumulation of mineralocorticoid precursors,
which do not need 17a-hydroxylation for their synthe-
sis. Adrenal hyperplasia and glucocorticoid deficiency
are less marked than in the other types of CAH
because of the ability of corticosterone to suppress
ACTH. Male patients affected by CAH due to 3b-
hydroxysteroid dehydrogenase (3bHSD) deficiency
display incomplete prenatal masculinization due to
Fig. 1 Steroidogenic pathway. Steroidogenic acute response protein (StAR) is involved in cholesterol transport through mitochondrial
membrane and not in an enzymatic step
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the impaired synthesis of bioactive androgens, and salt
loss due to lack of mineralocorticoid. XX subjects have
normal female external genitalia or mild virilization
due to the action of the weak androgen. Steroid 11b-
OHD, which is responsible for 10–20% of cases of
CAH, produces symptoms of androgen excess similar
to those in 21-OHD. The blocked enzymatic step also
results in accumulation of 11-deoxycorticosterone,
which has mineralocorticoid activity, leading to hyper-
tension in untreated patients.
Biochemistry
Steroid 21-hydroxylase (CYP21, also termed CYP21A2
and P450c21) is a cytochrome P450 enzyme located in
the endoplasmic reticulum. It catalyses the conversion
of 17-OHP to 11-deoxycortisol, a precursor of cortisol,
and the conversion of progesterone to deoxycorticos-
terone, a precursor of aldosterone (Fig. 1).
Patients with 21-OHD cannot synthesize cortisol
efficiently, and as a result, the adrenal cortex is
stimulated by corticotropin and overproduces cortisol
precursors. Some of these precursors are used for the
biosynthesis of sex hormones, which may cause signs of
androgen excess, including ambiguous genitalia in
newborn girls and rapid postnatal growth in both
sexes. Concomitant aldosterone deficiency may lead
to salt wasting with consequent failure to thrive,
hypovolaemia and shock.
Clinical presentation
Different phenotypes are observed. A severe form with
a concurrent defect in aldosterone biosynthesis (salt-
wasting type) and a form with apparently normal
aldosterone biosynthesis (simple virilizing type) are
called classic 21-OHD. There is also a mild, nonclassic
form that may be asymptomatic or associated with signs
of postnatal androgen excess (White and Speiser 2000).
Classic 21-OHD is detected in approximately 1 in
16 000 births in most populations (Therrell 2001). In
Switzerland, the disease is detected in approximately
1:10 000 with a carrier frequency of 1:50, which is in
agreement with figures of other European countries.
The nonclassic form occurs in approximately 0.2% of
the general white population but is more frequent
(1–2%) in certain populations, such as Jews of Eastern
European origin (Speiser et al 1985). The lower general
frequency is similar to that estimated on the basis of
CYP21 genotyping of newborns in New Zealand
(0.3%) (Fitness et al 1999).
Salt wasting
Approximately 75% of patients with classic 21-OHD
have severely impaired 21-hydroxylase activity and
therefore cannot adequately synthesize aldosterone.
Elevated levels of 21-hydroxylase substrates—mostly
17-OHP—may act as mineralocorticoid antagonists,
exacerbating the effects of aldosterone deficiency
(Oelkers 1996). Since aldosterone regulates sodium
homeostasis, renal sodium excretion in untreated
patients is excessive and can result in hypovolaemia
and hyperreninaemia. Such patients cannot excrete
potassium efficiently and are prone to hyperkalaemia,
especially in infancy. Cortisol deficiency in these
patients contributes to poor cardiac function, poor
vascular response to catecholamines, a decreased
glomerular filtration rate, and increased secretion of
antidiuretic hormone (Lamberts et al 1997). Thus,
cortisol and aldosterone deficiency together cause
hyponatraemic dehydration and shock in inadequately
treated patients. Moreover, since the development of
the adrenal medulla is in part dependent on glucocor-
ticoids, patients with salt-wasting 21-OHD may also
have catecholamine deficiency, potentially aggravating
shock (Merke et al 2000).
Patients with the salt-wasting form are identified
through the measurement of serum electrolytes, aldo-
sterone and plasma renin and the finding of expected
abnormalities, hyperkalaemia, low levels of aldoste-
rone and hyperreninaemia.
Ambiguous genitalia
Girls with classic 21-OHD are exposed in utero to high
levels of adrenal androgens from approximately the
seventh week of gestation. Thus, such girls have
ambiguous external genitalia. The uterus, Fallopian
tubes, and ovaries are normally formed, but there is no
development of the Wolffian duct. In contrast, affected
boys have no overt signs of the disease except variable
and subtle hyperpigmentation of the scrotum and
penile enlargement.
Postnatal virilization
In untreated or poorly treated patients, long-term
exposure to high levels of sex hormones promotes rapid
somatic growth and advanced skeletal age, which leads
to premature epiphyseal fusion and low adult height.
Pubic and axillary hair may develop early. Clitoral
growth may continue in girls. Young boys may have
penile growth despite having small testes, since the
androgens are adrenal in origin. Long-term exposure to
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androgens may activate the hypothalamic–pituitary–
gonadal axis, causing central precocious puberty.
Reproductive function
In girls with any form of 21-OHD, signs of reproduc-
tive abnormalities, such as oligomenorrhoea or ame-
norrhoea, may develop in adolescence (Barnes et al
1994; Deneux et al 2001). The issue of fertility is
mainly related to psychosocial adjustment. Women
with classic salt-wasting or simple virilizing disease who
were born and treated in the early days tend to avoid
heterosexual relationships, especially if the surgical
correction of the external genitalia was inadequate or
androgen levels were constantly elevated (Mulaikal
et al 1987).
As surgical, medical, and psychological treatments
have improved, more women with 21-OHD have
successfully completed pregnancies and given birth,
most by Caesarean section (Lo and Grumbach 2001;
Premawardhana et al 1997). About 80% of women
with simple virilizing disease and approximately 60%
of those with the severe salt-wasting form are fertile.
Compared with affected women, affected men have
fewer problems with reproductive function, specifically
gonadal function. Most have normal sperm counts and
are able to father children (Cabrera et al 2001; Urban
et al 1978). One relatively common form of gonadal
abnormality in affected males is the development of
testicular adrenal rests, detectable by sonographic
imaging before they become palpable (Stikkelbroeck
et al 2001). Such tumours have been detected even in
childhood (Murphy et al 2001), suggesting that the
search for them should begin no later than adoles-
cence. In males with salt wasting, testicular rest tissue
may be accompanied by deficient spermatogenesis
despite treatment. Infertility can be circumvented by
intracytoplasmic sperm injection (Walker et al 1997).
These tumours are always benign and orchidectomy is
usually not necessary. Proper medical treatment con-
sists of pituitary suppression with dexamethasone, since
the tumours are usually responsive to corticotropin.
Patients with simple virilizing 21-hydroxylase
deficiency
Patients with simple virilizing 21-OHD do not synthe-
size cortisol efficiently, but aldosterone secretion is
sufficient to maintain sodium balance. Whereas the
disease is usually diagnosed in female patients shortly
after birth due to genital ambiguity, the diagnosis is
often delayed for several years in male patients.
Without newborn screening, affected boys are usually
identified when signs of androgen excess develop.
Later diagnosis is associated with greater difficulty in
achieving hormonal control, abnormal tempo of pu-
berty, and short stature.
Patients with nonclassic disease
Patients with nonclassic 21-OHD produce normal
amounts of cortisol and aldosterone at the expense of
mild-to-moderate overproduction of sex hormone pre-
cursors. A few nonclassic cases are detected by
newborn-screening programmes, but most are missed
because of the relatively low baseline levels of 17-OHP
(Balsamo et al 1996; Tajima et al 1997; Therrell et al
1998). Hirsutism is the single most common symptom
at presentation in approximately 60% of symptomatic
women, followed by oligomenorrhoea (54%) and
acne (33%) (Moran et al 2000). Thus, nonclassic 21-
OHD and polycystic ovary syndrome may present in
similar ways.
Heterozygotes
Patients who are heterozygous for CYP21A2
mutations often have slightly higher 17-OHP levels
after adrenal stimulation than do unaffected subjects.
Although it has been suggested that heterozygotes
might be more likely to have signs of androgen excess
than would genetically unaffected subjects, case–control
studies do not support this concept (Knochenhauer
et al 1997).
Diagnosis
Screening
Classic 21-OHD is characterized by markedly elevated
serum levels of 17-OHP, the main substrate for the
enzyme. Basal serum 17-OHP values measured by
radioimmunoassay after extraction usually exceed
300 nmol/L in infants with classic CAH, whereas the
levels in normal newborns are below 3 nmol/L. This
difference makes it possible to screen newborns for the
disorder with the use of dried blood spots on filter
paper. Screening minimizes delays in diagnosis, espe-
cially in male patients, and reduces morbidity and
mortality from adrenal crises. One major problem in
CAH screening is posed by the fact that most
premature infants, especially those with gestational
ages of less than 31 weeks, have elevated 17-OHP
levels without having inborn errors in steroid biosyn-
thesis. This event is most likely due to physiologically
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delayed expression of the enzyme 11b-hydroxylase
(Hingre et al 1994). Elevation of 17-OHP levels in
both term and preterm babies can be also due to
illness, poor kidney or liver function, stress and
sampling before 48 h of life. It has therefore become
common practice to have different algorithms in CAH
screening, one for premature and one for term babies
(Figs. 2 and 3).
Another factor contributing to false elevations of
measured 17-OHP is the limited specificity of some
antisera used in the immunoassays of 17-OHP.
Particularly important is the cross-reactivity with
17-hydroxypregnenolone and its sulfate (up to 8%
cross-reactivity), compounds that tend to be rather
high in newborns (due to possible inhibition of
3bHSD by the maternal oestrogens).
Fig. 2 Example of a possible screening flowchart for term babies
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The high rate of false-positive values not only
increases the real cost of screening but also causes
psychological distress to the parents. Delays in accurate
diagnosis can lead either to unnecessary steroid therapy
or to failure to institute therapy in a timely manner.
Many screening programmes have therefore started to
perform routinely two tests in premature infants with
the aim of avoiding unnecessary recalls. This measure is
easy to implement and has proved to be effective in
reducing the rate of false-positive screening results and
in improving the positive predictive value of an elevated
17-OHP concentration (Steigert et al 2002).
Fig. 3 Example of a possible screening flowchart for premature newborns
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To further improve accuracy, some screening pro-
grammes have set reference levels for serum 17-OHP in
infants that are based on weight or gestational age (Fig. 4)
(Torresani et al 1994; van der Kamp et al 2005).
Recently it has been suggested that measurement of
17-OHP by tandem mass spectrometry may improve
both the sensitivity and the specificity of screening.
Tandem mass spectrometry (LC-MS/MS) might con-
stitute a reliable second-tier testing for CAH (Janzen
et al 2007; Minutti et al 2004) due to its high ability to
precisely identify metabolites (specificity close to
100%) and its capability to simultaneously recognize
several metabolites for the identification of defects
other than 21-OHD. Nevertheless, MS/MS cannot yet
be considered as an alternative for primary 17-OHP
measurement in a mass screening programme, mainly
because of its low sensitivity, the necessity for pre-
treatment of the sample (extraction) , the need of
preseparation of the metabolites (via gas chromatog-
raphy or liquid chromatography) and a relative long
time per run (up to 12 min, depending on the available
instrumentation). The utility of MS/MS measurement
as a second-tier method for confirming elevated levels
of 17-OHP has in any case already demonstrated its
value (Janzen et al 2007).
In recent years, molecular diagnosis has been
applied to confirm a diagnosis of CAH at the DNA
level. The advantages of this method as second-tier
testing rely on its high specificity. The recent report of
a 3bHSD (HSD3B2) deficiency identified by screening
(Nordenstrom et al 2007) indicates the possibility of
recognizing this deficiency in the neonatal period,
which does not seem to be the case for 11b-OHD
(CYP11B1).
Other diagnostic procedures
The gold standard for differentiating 21-OHD from
other steroidogenic enzyme defects is the corticotropin
(Synachten) stimulation test, performed by injecting a
0.125 mg or 0.25 mg bolus of ACTH and measuring
baseline and stimulated levels of 17-OHP. Blood
samples are obtained at baseline and 60 min after the
administration of ACTH. Except for premature infants,
there are no age-related differences in the criteria for
the diagnosis of 21-OHD on the basis of 17-OHP levels.
The severity of hormonal abnormalities depends on
the type of 21-OHD. Patients with salt-wasting disease
have the highest 17-OHP levels (up to 3000 nmol/L
after corticotropin stimulation), followed by patients
with simple virilizing disease, who usually have some-
what lower levels (300–1000 nmol/L). Patients with
nonclassic disease have smaller elevations (50–
300 nmol/L), especially in the newborn period. Ran-
dom measurements of basal serum 17-OHP levels are
often normal in patients with nonclassic disease unless
the values are obtained in the early morning. Thus, the
diagnosis is most reliably made by measuring the
patient_s response to corticotropin stimulation.
Other hormones whose levels are usually elevated
in patients with 21-OHD include progesterone,
androstenedione and, to a lesser extent, testosterone.
An atypical steroid, 21-deoxycortisol, is also elevated
but is not routinely assayed. Mutation analysis can
confirm the diagnosis and is used in some newborn-
screening programmes.
Genetics
Mutations in the CYP21 (CYP21A2) gene, which is
located in the highly polymorphic HLA histocompat-
ibility complex on chromosome 6p21.3 along with a
pseudogene, CYP21A1P (CYP21P), are responsible
for causing 21-OHD. Although CYP21A2 and
CYP21P have 98% nucleotide-sequence identity, the
latter has accumulated several mutations that totally
inactivate its gene product. These include an 8 bp
deletion in exon 3, a frameshift in exon 7, and a
nonsense mutation in exon 8 (Fig. 5). Additional
mutations in CYP21P affect messenger RNA (mRNA)
splicing or amino acid sequence. Most mutations
causing 21-OHD arise from two types of recombina-
tion between CYP21A2 and CYP21P. Approximately
3/4 represent deleterious mutations found in the
pseudogene that are transferred to CYP21 during
mitosis by a process termed Fgene conversion_. About
20% are meiotic recombinations that delete a 30 kb
Fig. 4 Normal values (expressed in centiles) of 17-hydroxypro-
gesterone related to gestational age (gestational week)
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gene segment that encompasses the 3¶ end of the
CYP21P pseudogene, all of the adjacent C4B comple-
ment gene, and the 5¶ end of CYP21A2, producing a
nonfunctional chimeric pseudogene.
The search for mutations is made easier since the
great majority (up to 95%) of the mutant alleles will
carry one of the 10 pseudogene mutations. On the
other hand, the high degree of sequence identity
between the active gene and the pseudogene renders
the specific amplification of the CYP21A2 active gene
rather challenging. The choice of primers hybridizing
exclusively to sequences of the active CYP21A2 gene
(e.g. in exon 3 where the active gene contains 8 bp that
are deleted in the pseudogene) helped to overcome
this hurdle.
Several new methods are currently used in the
molecular analysis of the CYP21A2 gene.
Large deletions
Southern blot analysis will reveal many aberrations but
will not always detect small deletions and is not a simple
to perform routine technique. Well-characterized dele-
tions and amplifications can be detected by PCR.
However, the exact breakpoint sites of most deletions
have not been determined. Furthermore, the number of
different deletions is becoming prohibitively large.
Multiplex ligation-dependent probe amplification
(MLPA; MRC Holland) (Schouten et al 2002)
Deletions and amplifications of (part of) a gene will
usually not be detected by sequence analysis of PCR-
amplified gene fragments as a normal copy is still
present. Analysis by MLPA is a suitable alternative
that is also capable of detecting new deletions and
amplifications.
With MLPA, it is possible to perform a multiplex
PCR reaction in which up to 45 specific sequences are
simultaneously quantified. Amplification products are
separated by sequence type electrophoresis. As only
one pair of PCR primers is used, MLPA reactions
result in a very reproducible gel pattern with fragments
ranging from 130 to 490 bp. Comparison of this gel
pattern with that obtained with a control sample
indicates which sequences show an aberrant copy
number (Fig. 6).
Other mutations
Ligase detection reaction (LDR) (Day et al 1995)
An equimolar mixture of two detecting (or allele-
specific) oligonucleotides and one common oligonu-
cleotide is hybridized to denatured PCR-amplified
targets. The detecting oligonucleotides anneal imme-
diately adjacent to the 5¶-end of the common oligonu-
cleotide, resulting in the formation of a short DNA
duplex containing a nick at the junction site between
the primers.
The two detecting primers are in competition for
hybridization to the denatured target, and depending
upon which of the detecting oligonucleotide has
hybridized, the 3¶-end of the allele-specific primer will
have a perfect match or will contain a single base
mismatch. If there is a match, then the junction
Fig. 5 Organization of the genomic region containing the 21-
hydroxylase active gene. Arrows indicate direction of transcrip-
tion. CYP21, 21-hydroxylase gene; CYP21P, 21-hydroxylase
pseudogene; C4A and C4B, genes encoding the fourth compo-
nent of serum complement; RP1, gene encoding a putative
nuclear protein of unknown function; RP2, truncated copy of
RP1; XB, tenascin–X gene; XA, truncated copy of XB. These
two sequences are on the opposite chromosomal strand
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between the detecting and the common primers will be
covalently sealed by DNA ligase.
We chose to differentiate the multiplex LDR
products on the basis of length and labelling. This
was achieved by synthesizing LDR oligonucleotides
with synthetic poly(dA) tails such that each ligation
product has a unique length, two nucleotides different
from that of any other ligation product. At each gene
Fig. 6 Multiplex ligase-dependent probe amplification: general
scheme of method (copyright MRC Holland, from Schouten et al
2002; www.mrc-holland.com). (A) MLPA probes. (B) The
MLPA probe mix is added to denatured genomic DNA. The
two parts of each probe hybridize to adjacent target sequences.
(C) Probes are ligated by a thermostable ligase. (D) A universal
primer pair is used to amplify all ligated probes. The amplification
product of each probe has a unique length. (E) Separation and
quantification by capillary electrophoresis. Each peak is the am-
plification product of a specific probe. Samples are compared with
a control sample. A difference in relative peak height or peak area
indicates a copy number change of the probe target sequence
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conversion site the CYP21P product was always two
bases longer than the corresponding CYP21A2 prod-
uct. The CYP21A2 products were each four bases
longer than the previous going from the 5¶ to 3¶ end of
the gene (Fig. 7). An example of an output of this
analysis is depicted in Fig. 8.
Fig. 7 Ligase detection reaction: principle. Detecting (or allele-
specific) oligonucleotides and one common oligonucleotide are
hybridized to denatured PCR-amplified targets. The detecting
oligonucleotides anneal immediately adjacent to the 5¶-end of the
common oligonucleotide, resulting in the formation of a short DNA
duplex containing a nick at the junction site between the primers. If
there is a match, then the junction between the detecting and the
common primers will be covalently sealed by DNA ligase. We
chose to differentiate the multiplex LDR products on the basis of
length and labelling (see text for further details)
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Additional methods
Minisequencing (Krone et al 2002) is based on the
same principle as LDR, with a second DNA-polymer-
ase step instead of the ligase reaction.
The amplicon melting curve method is based on
analysis of the melting curve of amplified DNA
fragments (amplicons). DNA melts at characteristic
melting temperatures (Tm) that are defined as the
temperatures where half of the helical structure of the
DNA is lost. These structural changes can be assayed
by capillary electrophoresis of the target fragments at
increasing temperatures (melting curve). The detection
is based on fluorescent tags (e.g. SYBR Green). Since
the differences in Tm are directly dependent on the
nucleotide composition of the DNA, melting curve
analysis allows distinction between DNA fragments of
different composition. (for more information http://
www.roche-applied-science.com). As for LDR, this
technique allows detection of known mutations only.
Sequencing for the detailed analysis of the whole
sequence of the CYP21A1 gene is still the only genetic
analysis with 100% detection rate, but its use is not yet
broadly established.
Genotype–phenotype correlation
CYP21 mutations can be grouped into three categories
according to the level of enzymatic activity predicted
from in vitro mutagenesis and expression studies. The
first group consists of so-called null mutations (dele-
tions or nonsense mutations) that totally abolish
enzyme activity; these are most often associated with
salt-wasting disease (Speiser and White 2003). The
second group of mutations, consisting mainly of the
missense mutation Ile172Asn (I172N) yields enzymes
Fig. 8 Output of LDR reaction in normal DNA (control) and
three patients: patient 1 was a 13-year-old girl with signs of
hyperandrogenism and a borderline 17-hydroxyprogesterone
(20 nmol/L) after ACTH injection. Patient 2 was a newborn
boy at term with 670 nmol/L 17-hydroxyprogesterone at screen-
ing. Patient 3 was a term-born girl who had basal mildly ele-
vated 17-hydroxyprogesterone at screening (64 nmol/L) and
after ACTH (88 nmol/L). The molecular genetic assay excluded
a CAH in patient 1 and confirmed classic CAH in patients 2
and 3
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with reduced activity (1–2% of normal). These muta-
tions permit adequate aldosterone synthesis and are
associated with simple virilizing disease. The final
group includes mutations such as Val281Leu (V281L)
and Pro30Leu (P30L) that produce enzymes retaining
20–60% of normal activity; these mutations are
associated with the nonclassic disorder.
When the 21-OHD phenotype is quantitated with
the use of 17-OHP levels or scores for signs of
androgen excess or salt wasting, a phenotype–genotype
correlation of 80–90 % is found. Compound hetero-
zygotes for two different CYP21 mutations usually
have a phenotype compatible with the presence of the
milder of the gene defects (Speiser et al 1992).
Treatment
CAH is a chronic disease that requires long-term
therapy. In the classic form of the disease glucocorti-
coids are required not only to overcome the cortisol
deficiency mostly in stress situations, but also to
suppress the ACTH-driven stimulation of andrenal
androgens. In 75% of the cases, mineralocorticoids
substitution is required and salt supplementation is
advisable in infancy. Surgical correction of the ambig-
uous genitalia in girls is also part of the management of
these patients. It is not recommended to treat infants
and children affected by the nonclassic form of the
disease until symptoms and signs of androgen excess
become evident. For more details on this topic, see
Speiser and White (2003).
Conclusions
Recent advances in the diagnostic procedure of CAH
have dramatically improved the management of the
disease, not only in the early phases of life thanks to
the newborn screening but also in the prenatal period
thanks to reliable genetic analysis.
By using gestational age-related cut-off values in
newborn screening the number of unwanted recalls,
particularly in premature infants, has been significantly
reduced. The advent of tandem mass-spectrometry has
opened further possibilities for more specific and
targeted analysis for the screening and beyond.
Finally, a genetically well-characterized disease such
as 21-hydroxylase deficiency might eventually be a
target for gene therapy. Since this therapeutic ap-
proach is still costly in time and investment, the
selection of the patients and implementation of such
an approach for this as well as other metabolic diseases
must be further improved.
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